The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

As Trump appointee and vaccine skeptic RFK Jr. looks toward Washington, Novartis (NVS) CEO Vas Narasimhan is concerned about ...

Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

CEO Vas Narasimhan said the results marked a positive early signal since implementing a strategic overhaul in 2023 to ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...